December 01, 2016

Today's Top Alzheimer's News

MUST READS & WATCH 

Must Watch: U.S. Senator Bob Menendez marked Alzheimer’s Awareness Month by visiting with a team of Rutgers University researchers developing a revolutionary treatment for the devastating neurological disorder. The senator—whose late mother, Evangelina, suffered from Alzheimer’s—renewed his commitment to fight for greater federal funding to help find effective treatments and a cure. Watch here.

A December 1, 2016 The Hill article and video highlighted an event with Eli Lilly and The Hill about overcoming Alzheimer’s by 2025. According to the article, “The National Alzheimer's Project Act, passed unanimously by Congress in December 2010, set the stage for the creation of a national strategic plan to address the public health crisis posed by Alzheimer's disease. Released in 2012, the National Plan to Address Alzheimer's Disease set an ambitious goal to prevent and effectively treat Alzheimer's disease by 2025.”

A November 30, 2016 Police One opinion piece by Melissa Mann highlighted “How specialized training on dementia can help cops save lives.” According to the article, “Law enforcement agencies across the U.S. are diligently working to increase knowledge and awareness of Alzheimer's and dementia persons. Today, there are a variety of resources and tools available to law enforcement communities. Awareness, training and education are the keys to successful interactions with those suffering from Alzheimer’s or other types of dementia.”

A November 30, 2016 CBS News article captured the reactions of viewers to Sunday’s 60 Minutes segment about Alzheimer’s. 

A November 30, 2016 Medscape.com article reported that “Neuronix Ltd has announced that topline results from its recently completed multinational, randomized clinical trial of the neuroAD Therapy System for patients with mild to moderate Alzheimer's disease (AD) were so positive it will be seeking regulatory clearance from the US Food and Drug Administration (FDA).”

A November 30, 2016 Market Realist article explored the question: “Can AbbVie’s Anti-Tau Therapeutics Help Late-Stage Alzheimer’s Patients?” According to the article, “In AbbVie’s R&D Day transcript, the company explained that there may be significant chances of preserving cognition in patients if anti-tau therapies are administered in the early stage of the disease. AbbVie also believes anti-tau therapeutics can also be effective in later stages of the disease.”